Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29

Structure Therapeutics Inc. (NASDAQ:GPCRGet Free Report) has received an average rating of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $81.29.

Several research firms recently issued reports on GPCR. Morgan Stanley assumed coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. JMP Securities reissued a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd.

View Our Latest Analysis on GPCR

Structure Therapeutics Stock Down 0.4 %

Shares of NASDAQ GPCR opened at $25.16 on Thursday. The stock’s 50 day moving average price is $31.74 and its two-hundred day moving average price is $36.37. Structure Therapeutics has a 52-week low of $23.50 and a 52-week high of $62.74. The stock has a market capitalization of $1.44 billion, a P/E ratio of -34.00 and a beta of -2.78.

Institutional Trading of Structure Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Natixis Advisors LLC increased its holdings in shares of Structure Therapeutics by 29.4% during the second quarter. Natixis Advisors LLC now owns 19,005 shares of the company’s stock valued at $746,000 after purchasing an additional 4,321 shares during the period. TD Asset Management Inc increased its stake in Structure Therapeutics by 47.9% during the 2nd quarter. TD Asset Management Inc now owns 211,590 shares of the company’s stock valued at $8,309,000 after buying an additional 68,490 shares during the period. Pier Capital LLC increased its stake in Structure Therapeutics by 3.7% during the 2nd quarter. Pier Capital LLC now owns 101,204 shares of the company’s stock valued at $3,974,000 after buying an additional 3,647 shares during the period. American Century Companies Inc. raised its position in shares of Structure Therapeutics by 66.4% during the 2nd quarter. American Century Companies Inc. now owns 434,982 shares of the company’s stock worth $17,082,000 after buying an additional 173,523 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in shares of Structure Therapeutics by 6.6% in the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock worth $94,531,000 after acquiring an additional 150,000 shares during the period. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

(Get Free Report

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Featured Articles

Analyst Recommendations for Structure Therapeutics (NASDAQ:GPCR)

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.